Ironwood Pharmaceuticals, Inc.

IRWD

US46333X1081

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:20:14 2024-04-26 am EDT			5-day change	1st Jan Change
8.065 ^USD	-0.19%		+2.08%	-29.33%

Mar. 28	Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	CI
Feb. 29	Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	MT

Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Full Year 2022

January 10, 2022 at 07:34 am EST

Ironwood Pharmaceuticals, Inc. provided financial guidance for the full year 2022. For the year, the company expects total revenue of $420 million to $430 million.

Latest news about Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	Mar. 28	CI
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	Feb. 29	MT
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	Feb. 29	MT
Top Premarket Decliners	Feb. 29	MT
Transcript : Ironwood Pharmaceuticals, Inc. - Special Call	Feb. 29
Ironwood says bowel disease treatment meets main goal in late-stage trial	Feb. 29	RE
Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $21 From $20, Maintains Overweight Rating	Feb. 16	MT
Ironwood Pharmaceuticals Insider Sold Shares Worth $2,699,979, According to a Recent SEC Filing	Feb. 15	MT
Ironwood Pharmaceuticals Insider Sold Shares Worth $588,538, According to a Recent SEC Filing	Feb. 15	MT
Ironwood Pharmaceuticals Insider Sold Shares Worth $722,071, According to a Recent SEC Filing	Feb. 15	MT
Ironwood Pharmaceuticals Q4 Non-GAAP Net Income Drops, Revenue Rises	Feb. 15	MT
Transcript : Ironwood Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Feb. 15	CI
(IRWD) IRONWOOD PHARMACEUTICALS Expects Fiscal Year 2024 Revenue Range $435M - $455M	Feb. 15	MT
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Posts Q4 Revenue $117.6M	Feb. 15	MT
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q4 EPS $-0.00	Feb. 15	MT
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Feb. 15	CI
Craig-Hallum Starts Coverage on Ironwood Pharmaceuticals with Buy Rating, $21 Price Target	Jan. 17	MT
Transcript : Ironwood Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11:15 AM	Jan. 10
Ironwood Pharmaceuticals 2024 Revenue Outlook Trails Consensus; 2023 Guidance Maintained	Jan. 08	MT
Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Fiscal Year 2023 and Provides Earnings Guidance for the Fiscal Year 2024	Jan. 08	CI
Transcript : Ironwood Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
(IRWD) IRONWOOD PHARMACEUTICALS Expects Fiscal Year 2023 Revenue Range $435M - $450M	Nov. 09	MT

Chart Ironwood Pharmaceuticals, Inc.

Duration

Period

More charts

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ironwood Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.08 USD

Average target price

17.4 USD

Spread / Average Target

+115.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IRONWOOD PHARMACEUTICALS, INC.	-29.33%	1.26B
IQVIA HOLDINGS INC.	+1.54%	42.59B
MODERNA, INC.	+8.30%	40.65B
LONZA GROUP AG	+48.88%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.05%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.18%	18.17B
MEDPACE HOLDINGS, INC.	+28.22%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.05%	11.7B
UNITED THERAPEUTICS CORPORATION	+7.55%	11.1B

Other Biotechnology & Medical Research